US-based Boston Scientific has completed the patient enrolment in the EVOLVE II clinical trial, designed to assess the safety and effectiveness of SYNERGY stent system and support the US Food and Drug Administration and Japanese regulatory ...
Tags: Clinical Trial, Medicine
US-based medical technology provider Boston Scientific said it is launching the new polymer-based drug-eluting stent (DES) system in the European market as the product has obtained CE mark approval. The Promus Premier everolimus-eluting ...
Boston Scientific has obtained CE mark approval for its Synergy Everolimus-Eluting platinum chromium coronary stent system, designed to improve post-implant vessel healing. The coronary stent, which features a combination of ...
Boston Scientific has received the US Food and Drug Administration (FDA) approval for 32 mm and 38 mm lengths of the Promus Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent system. The Promus Element Stent is made with a ...
Tags: FDA, Boston Scientific, Promus Element Stent, coronary artery disease
Boston Scientific has completed enrolling first patient in a EVOLVE II clinical trial of its Synergy Everolimus-Eluting platinum chromium coronary stent system. The CE-marked stent features a combination of everolimus drug and ...
Tags: Synergy Everolimus Eluting platinum chromium coronary stent system